Research programme: rhinovirus replication inhibitors - Bristol-Myers Squibb
Latest Information Update: 16 Jan 2008
At a glance
- Originator Bristol-Myers Squibb
- Class Small molecules
- Mechanism of Action Rhinovirus replication inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Rhinovirus infections
Most Recent Events
- 31 May 2004 Phase-I clinical trials in Rhinovirus infections in USA (unspecified route)